Paul Tudor Jones's BBIO Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 77,170 shares of BridgeBio Pharma, Inc. (BBIO) worth $5.75 M, representing 0.01% of the portfolio. First purchased in 2021-Q2, this medium-term investment has been held for 16 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in BBIO, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2025, adding 91,332 shares. Largest reduction occurred in Q3 2025, reducing 124,068 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's BridgeBio Pharma (BBIO) Holding Value Over Time
Track share changes against reported price movement
Quarterly BridgeBio Pharma (BBIO) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +77,170 | New Buy | 77,170 | $74.48 |
| Q3 2025 | -124,068 | Sold Out | 0 | $0.00 |
| Q2 2025 | +32,736 | Add 35.84% | 124,068 | $43.18 |
| Q1 2025 | +91,332 | New Buy | 91,332 | $34.57 |
| Q2 2024 | -22,164 | Sold Out | 0 | $0.00 |
| Q1 2024 | +22,164 | New Buy | 22,164 | $30.92 |
| Q4 2023 | -81,150 | Sold Out | 0 | $0.00 |
| Q3 2023 | +81,150 | New Buy | 81,150 | $26.37 |
| Q2 2023 | -23,321 | Sold Out | 0 | $0.00 |
| Q1 2023 | -51,187 | Reduce 68.70% | 23,321 | $0.02 |
| Q4 2022 | -5,218 | Reduce 6.54% | 74,508 | $0.01 |
| Q3 2022 | +79,726 | New Buy | 79,726 | $9.93 |
| Q1 2022 | -120,372 | Sold Out | 0 | $0.00 |
| Q4 2021 | +29,679 | Add 32.72% | 120,372 | $16.68 |
| Q3 2021 | +43,630 | Add 92.71% | 90,693 | $46.87 |
| Q2 2021 | +47,063 | New Buy | 47,063 | $60.96 |
Paul Tudor Jones's BridgeBio Pharma Investment FAQs
Paul Tudor Jones first purchased BridgeBio Pharma, Inc. (BBIO) in Q2 2021, acquiring 47,063 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held BridgeBio Pharma, Inc. (BBIO) for 16 quarters since Q2 2021.
Paul Tudor Jones's largest addition to BridgeBio Pharma, Inc. (BBIO) was in Q1 2025, adding 91,332 shares worth $3.16 M.
According to the latest 13F filing for Q2 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 77,170 shares of BridgeBio Pharma, Inc. (BBIO), valued at approximately $5.75 M.
As of the Q2 2026 filing, BridgeBio Pharma, Inc. (BBIO) represents approximately 0.01% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in BridgeBio Pharma, Inc. (BBIO) was 124,068 shares, as reported at the end of Q2 2025.